Пребарување (Вести)

Innovent Announces First Patient Dosed In Pivotal Registrational Study Of IBI363/TAK-928 (PD-1/IL-2Α-Biased Bispecific Fusion Protein) In Combination With Bevacizumab In Late-Line Advanced Colorectal Cancer In China

english top health

(MENAFN - PR Newswire) SAN FRANCISCO and SUZHOU, China, Aug. 5, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, ...
2026-08-05 20:16:19